approved glp-1 agonists Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care Visible Alpha GLP-1 drug monitor
Description
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: A randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
More recently, the FDA has approved several GLP-1 agonists for weight loss in people with obesity who do not have diabetes
Marx N, Davies MJ, Grant PJ, et al
A systematic review ScienceDirect science/article/pii/S2214623724000048 [58] GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)
All patients were closely tracked for up to 5 years for any occurrence of the outcome of interests
